Psychedelics were widely researched in the mid-1900s until many fell under strict government control and reclassification as schedule I drugs having no medicinal use. The term psychedelics was coined by psychiatrist Humphrey Osmond and means "mind-manifesting." Interestingly, each country seems to have their own definition and understanding of what psychedelics are. One commonality among psychedelics is a heightened sensory experience. More recently, studies have shown promising treatments for many psychological disorders using psychedelics including major depression. Universities and private companies are taking interest in psychedelics, forming startups and securing patents. This Patent Forecast® is concerned with the classic psychedelics, as defined by the NIH, including LSD, DMT, Psilocybin, Peyote, and NBOM US patent filings for the past 5 years.
| Corporation | Patents and Published Applications Count |
|---|---|
1.
Charleston Laboratories
|
|
2.
Fungi Perfecti
|
|
3.
Pop Test Abuse Deterrent Technology
|
|
| 4. Inventor |
|
5.
Arena Pharmaceuticals
|
|
6.
Compass Pathways
|
|
7.
Syqe Medical
|
|
8.
Redx Pharma
|
|
9.
CaaMTech
|
|
10.
Vectura Group
|
|
| Categorization and Classification | Patents and Published Applications |
|---|---|
| 96 | |
| 96 Psychedelic Options | |
| 34 | |
| 34 Psilocybin | |
| 32 | |
| 32 LSD | |
| 15 | |
| 15 Psilocybin/Psilocin | |
| 6 | |
| 6 Seratonin 2A Modulator | |
| 5 | |
| 5 Psilocin | |
| 4 | |
| 4 Peyote | |
| 4 | |
| 4 DMT | |
